Canaccord Genuity analyst John Young CFA maintained a Buy rating on Pulmonx (LUNG – Research Report) yesterday and set a price target of $16.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
John Young CFA has given his Buy rating due to a combination of factors demonstrating Pulmonx’s strong financial performance and strategic initiatives. The company exceeded revenue expectations in the fourth quarter of 2024, particularly in international markets, indicating solid growth potential. Additionally, Pulmonx’s effective expense management contributed to better-than-expected profitability, showcasing their operational efficiency.
Furthermore, the management’s guidance for 2025 aligns with the positive trends observed, suggesting continued growth through strategic initiatives like “Acquire, Test, Treat” to enhance market penetration and patient management. The company aims for a 20% long-term revenue growth, supported by a focus on the Zephyr therapy, which, despite its complexity, targets an underserved market. This strategic direction, coupled with a compelling valuation and limited competition, underpins the Buy rating from John Young CFA.
According to TipRanks, Young CFA is a 4-star analyst with an average return of 21.3% and a 73.91% success rate. Young CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Staar Surgical, and AngioDynamics.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.